羧甲司坦联合盐酸氨溴索注射液对慢性阻塞性肺疾病急性加重期患者血气及炎症的影响  

Effect of Carbocisteine combined with Ambroxol Hydrochloride Injection on blood gas and inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：刘秀丽 胡瑞玲 葛艳萍 Liu Xiu-li;Hu Rui-ling;Ge Yan-ping(Department of Emergency Medicine,Xiangfu District Hospital of Traditional Chinese Medicine,Kaifeng 475000,Henan,China;Emergency Department,Kaifeng People's Hospital,Kaifeng 475000,Henan,China)

机构地区：[1]祥符区中医院急诊内科,河南开封475000 [2]开封市人民医院急诊科,河南开封475000

出　　处：《四川生理科学杂志》2025年第1期209-212,共4页

摘　　要：目的:研究羧甲司坦联合盐酸氨溴索注射液治疗慢性阻塞性肺疾病急性加重期(Acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者的效果。方法:回顾性分析2022年1月至2024年2月于我院就诊的83例AECOPD患者资料,按治疗方案不同分为单药组(n=43)和联合组(n=40)。单药组患者给予30 mg盐酸氨溴索注射液与0.9%氯化钠注射液100 mL混合后静脉注射治疗,2次·d^(-1)。联合组患者基于单药组加用0.5 g·次^(-1)羧甲司坦口服治疗,3次·d^(-1)。比较两组临床疗效,于治疗前后评估并对比慢性阻塞性肺病自我评估测试(Copd assessment test,CAT)、圣乔治呼吸问卷(St george's breathing questionnaire,SGRQ)评分,于治疗前后采用肺功能仪检测第一秒用力呼气量(Forced expiratory volume in the first second,FEV_(1))、用力肺活量(Forced vital capacity,FVC)、FEV_(1)与FVC比值(FEV_(1)/FVC),于治疗前后采集患者桡动脉血1 mL,采用全自动血气分析仪检测动脉血氧饱和度(Arterial oxygen saturation,SaO_(2))、动脉血氧分压(Arterial partial pressure of oxygen,PaO_(2))、动脉血二氧化碳分压(Arterial carbon dioxide partial pressure,PaCO_(2)),于治疗前后经放射免疫吸附试验法检测血清免疫球蛋白E(Immunoglobulin E,IgE),经酶联免疫吸附法检测血清高迁移率族蛋白1(High Mobility Group Protein 1,HMGB1)、白细胞介素-17(Interleukin-17,IL-17)、IL-18、肿瘤坏死因子-α(Tumor Necrosis Factor alpha,TNF-α),分析比较治疗期间两组的胃部不适、腹泻、皮疹总发生率。结果:联合组总有效率高于单药组(P<0.05);组间不良反应总发生率无明显差异(P>0.05);治疗后联合组CAT、SGRQ评分较单药组低(P<0.05);治疗后两组FVC、FEV_(1)/FVC、FEV_(1)、PaO_(2)、SaO_(2)上升,PaCO_(2)、TNF-α、IgE、IL-18、HMGB1、IL-17下降,其中联合组改善幅度更为明显(P<0.05)。结论:羧甲司坦与盐酸氨溴索注射液联合治疗AECOPD患者的效果显著,可明显减轻Objective:To study the effect of carbomesteine combined with ambroxol hydrochloride injection in treating acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:Retrospective analysis of the data of 83 patients with AECOPD who were treated in our hospital from January 2022 to February 2024 was conducted.The patients were divided into a single-drug group(n=43)and a combination group(n=40)based on different treatment regimens.The patients in the single-drug group were treated with 30 mg of ambroxol hydrochloride injection mixed with 100 mL of 0.9%sodium chloride injection for intravenous injection twice a day.The patients in the combination group were treated with 0.5 g of oral carbazochrome acetate plus 0.5 g of oral acetylcysteine twice a day.The clinical efficacy of the two groups was compared by evaluating and comparing the scores of the COPD assessment test(CAT)and St george's breathing questionnaire(SGRQ)before and after treatment.The forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),and FEV1/FVC ratio were measured using a pulmonary function instrument before and after treatment.The blood samples from the radial artery of the patients were collected for 1 mL,and the arterial oxygen saturation(SaO_(2)),arterial partial pressure of oxygen(PaO_(2)),and arterial carbon dioxide partial pressure(PaCO_(2))were measured using a fully automated blood gas analyzer.The serum immunoglobulin E(IgE),High Mobility Group Protein 1(HMGB1),interleukin-17(IL-17),tumor necrosis factor alpha(TNF-α),and tumor necrosis factor alpha(TNF-α)were detected by radioimmunoassay before and after treatment.The total incidence of gastric discomfort,diarrhea,and rash in the two groups during the treatment period was analyzed and compared.Results:The total effective rate of the combination group was higher than that of the single-drug group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The CAT and SGRQ scores of the comb

关 键 词：羧甲司坦 盐酸氨溴索注射液 慢性阻塞性肺疾病 血气分析 

分 类 号：R563.5[医药卫生—呼吸系统]